Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy.
Goldberg
Richard M
RM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005060:Europe; D019317:Evidence-Based Medicine / Q000379:methods*; D006801:Humans; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C400149:Edrecolomab